HCW Biologics' Alopecia Drug HCW9302 Shows Positive Phase 1 Results, All Patients Respond in Key Cohort
HCWB has more than doubled off its 52-week low of $0.25.
Summary
HCW Biologics announced positive preliminary Phase 1 results for its IL-2 based immunotherapeutic, HCW9302, in alopecia areata. All three participants in the second dose cohort (3 micrograms/kg) showed a >=25% reduction in SALT scores, indicating clinical improvement. The drug was well-tolerated with no dose-limiting toxicities or serious IL-2 related adverse effects. This positive clinical development provides a crucial boost for the company, which has recently faced a going concern warning, Nasdaq delisting threat, and has been actively raising capital and seeking a reverse stock split. The company aims to establish the Recommended Phase 2 Dose by year-end 2026.
At the time of this announcement, HCWB was trading at $1.50 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $8.7M. The 52-week trading range was $0.25 to $7.35. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.